Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.

European Heart Journal
Jackie BoschSalim Yusuf

Abstract

Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) events by 24% in 12 705 participants at intermediate CV risk after 5.6 years. There was no benefit of blood pressure (BP) lowering treatment in the overall group, but a reduction in events in the third of participants with elevated systolic BP. After cessation of all the trial medications, we examined whether the benefits observed during the active treatment phase were sustained, enhanced, or attenuated. After the randomized treatment period (5.6 years), participants were invited to participate in 3.1 further years of observation (total 8.7 years). The first co-primary outcome for the entire length of follow-up was the composite of myocardial infarction, stroke, or CV death [major adverse cardiovascular event (MACE)-1], and the second was MACE-1 plus resuscitated cardiac arrest, heart failure, or coronary revascularization (MACE-2). In total, 9326 (78%) of 11 994 surviving Heart Outcomes Prevention Evaluation (HOPE)-3 subjects consented to participate in extended follow-up. During 3.1 years of post-trial observation (total follow-up of 8.7 years), participants originally randomized to rosuvastatin compared with placebo had a 20% additio...Continue Reading

Associated Clinical Trials

May 3, 2007·Salim Yusuf's office

References

Mar 15, 2006·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN ASTEROID Investigators
May 8, 2008·Journal of Cardiovascular Pharmacology and Therapeutics·Michael S KostapanosMoses S Elisaf
Mar 8, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Han-lu LvDeng-feng Geng
Sep 20, 2015·BMC Medicine·Maciej BanachUNKNOWN Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
Oct 10, 2015·BMC Medicine·Marcio Sommer Bittencourt, Rodrigo Julio Cerci
Apr 5, 2016·The New England Journal of Medicine·Salim YusufUNKNOWN HOPE-3 Investigators
Apr 5, 2016·The New England Journal of Medicine·Eva M LonnUNKNOWN HOPE-3 Investigators
Aug 9, 2016·Cardiovascular Diagnosis and Therapy·Kohei TakataKeijiro Saku
Nov 16, 2016·JAMA : the Journal of the American Medical Association·Stephen J NichollsSteven E Nissen
Aug 31, 2018·European Heart Journal·Bryan WilliamsUNKNOWN ESC Scientific Document Group
Sep 11, 2019·European Heart Journal·François MachUNKNOWN ESC Scientific Document Group
Nov 14, 2020·The New England Journal of Medicine·Salim YusufUNKNOWN International Polycap Study 3 Investigators

❮ Previous
Next ❯

Citations

May 7, 2021·European Heart Journal·Eric Boersma, Isabella Kardys

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.